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Abstract
We previously reported that Candida albicans cell surface protein Hyr1 encodes a phagocyte killing resistance factor and
active vaccination with a recombinant N-terminus of Hyr1 protein (rHyr1p-N), significantly protects immunocompetent mice
from disseminated candidiasis. Here we report the marked efficacy of rHyr1p-N vaccine on improving the survival and
reducing the fungal burden of disseminated candidiasis in both immunocompetent and immunocompromised mice using
the FDA-approved adjuvant, alum. Importantly, we also show that pooled rabbit anti-Hyr1p polyclonal antibodies raised
against 8 different peptide regions of rHyr1p-N protected mice in a hematogenously disseminated candidiasis model,
raising the possibility of developing a successful passive immunotherapy strategy to treat this disease. Our data suggest
that the rabbit anti-Hyr1p antibodies directly neutralized the Hyr1p virulence function, rather than enhanced
opsonophagocytosis for subsequent killing by neutrophil in vitro. Finally, the rHyr1p-N vaccine was protective against
non-albicans Candida spp. These preclinical data demonstrate that rHyr1p-N is likely to be a novel target for developing
both active and passive immunization strategies against Candida infections.
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Introduction
Candida species, the third most common cause of healthcare-
associated bloodstream infections [1] causes approximately 60,000
cases of hematogenously disseminated candidiasis per year in the
United States [2], resulting in billions of dollars of healthcare
expenditures. Notwithstanding current antifungal therapy [3,4,5],
mortality remains unacceptably high [6,7,8]. Because of the rising
incidence of life-threatening candidiasis and high treatment failure
rates, more effective prophylactic and therapeutic strategies are
needed.
HYR1 belongs to the IFF gene family of C. albicans, which
includes 12 members [9]. It encodes a cell surface glycosylpho-
sphatidylinositol (GPI)-anchored protein that is expressed during
hyphal formation [10,11]. In our previous study, we showed that
Hyr1p mediated C. albicans resistance to phagocyte killing in vitro
and contributed higher fungal burden in organs rich in phagocytes
(e.g. liver and spleen) [12]. Native HYR1 is positively regulated by
transcription factor Bcr1p [13]. We found that autonomous HYR1
expression reversed the hyper-susceptibility to phagocyte-mediated
killing of a bcr1 null mutant of C. albicans in vitro [12]. Further,
heterologous expression of HYR1 in C. glabrata rendered the
organism more resistant to phagocyte killing [12]. Our study also
showed that a vaccine based on the recombinant N terminus of
Hyr1p (rHyr1p-N) markedly improved survival of immunocom-
petent mice challenged intravenously with C. albicans when mixed
with either Freund’s or alum as an adjuvant [12].
The current studies were performed to further define the
vaccine efficacy of rHyr1p-N vaccine in both immunocompetent
and immunocompromised mice using the FDA-approved alum as
an adjuvant. Further, the breadth of protection induced by
rHyr1p-N was evaluated by its efficacy against non-albicans Candida
species. Finally, we sought to study the potential use of passive
immune therapy in disseminated candidiasis using anti-Hyr1p
antibodies.
Results
The rHyr1p-N vaccine significantly improved survival and
decreased fungal burden in immunocompetent mice
challenged intravenously with C. albicans
To determine the most effective dose of the rHyr1p-N
immunogen, an approximately 3-fold dose range was evaluated
(1 to 33 mg per mouse). Female juvenile BALB/c mice were
immunized with rHyr1p-N plus alum (2% Alhydrogel; Brenntag
Biosector) or with alum alone. These mice were subsequently
infected with a lethal inoculum of C. albicans (76105 blastospores).
Vaccinated mice had significant improvements in survival
compared to adjuvant control mice (Figure 1A). All tested doses,
except 1 mg, prolonged or improved survival compared to mice
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receiving adjuvant alone, and a dose response was found with 10
and 33 mg having the greatest efficacy (Figure 1A). The
experiment was terminated on day 28, with all remaining mice
appearing healthy.
To determine the impact of vaccination on fungal burden,
juvenile mice were vaccinated and infected as above. On day 3
post-infection (one day before the control mice were predicted to
die based on the previous experiment), mice were euthanized and
kidneys, being the primary target organ, were harvested to
determine tissue fungal burden. Vaccination reduced the tissue
fungal burden by approximately 16-fold compared to control mice
(p,0.001) (Figure 1B).
Consistent with the survival and fungal burden data, histopath-
ological examination of kidneys harvested from rHyr1p-N
vaccinated mice demonstrated very few abscesses with minimal
fungal residues mainly present in the blastospore formation
(Figure 2B). However, numerous abscesses full of fungal cells
showing mostly yeast forms with some hyphae and pseudohyphae
were detected in kidneys taken from mice vaccinated with alum
alone (Figure 2A). Semi-quantitative evaluation of the severity of
infection showed a significant reduction of abscesses per field as
well as reduced Candida cells per abscess in vaccinated mice
compared to that in controls (Fig. 2C, P,0.0001).
The rHyr1p-N effectively protected
immunocompromised mice against candidiasis
It is known that a significant fraction of immunocompromised
patients do respond to a variety of vaccines [14,15,16,17]. We sought
to define the potential usage of the rHyr1p-N vaccine to protect
neutropenic mice from disseminated candidiasis. Immunized mice
were bled twelve days following the boost with 30 mg of rHyr1p-N.
Vaccination significantly increased the mouse immune response as
determined by detection of increased anti-rHyr1p-N antibody titers
(P= 1.08E-05) (Figure 3A). One day after the bleeding, mice were
made neutropenic. Vaccination resulted in significant improvements
in survival (P= 0.007 versus control) (Figure 3B).
We also evaluated the kidney fungal burden on day 10 post
infection. Concordant with our survival result, we found that mice
vaccinated with 30 mg of rHyr1p-N had 1.50 log fold decrease in
fungal burden compared to kidneys harvested from control mice
(Figure 3C, P= 0.002).
Passive immunization with anti-Hyr1p IgG prolonged the
survival of mice infected with C. albicans
Since some patients might not respond to an active vaccine
strategy, we evaluated the possibility of using passive immuno-
therapy targeting Hyr1p. We generated polyclonal antibodies by
vaccinating rabbits with 8 hydrophilic, highly antigenic 14-mer
peptides located within rHyr1p-N region (Table 1). Purified IgG
targeting these 8 peptides were pooled and used to treat naı¨ve mice
infected with a lethal dose of C. albicans. Mice receiving anti-Hyr1p
IgG at either 1 or 3 mg (but not when administered at 0.3 mg)
were protected substantially from infection when compared to
mice receiving non-specific, rabbit control IgG from commercial
source (Figure 4A, 4B and 4C).
To determine if the generated anti-Hyr1p antibodies enhanced
phagocyte function by increasing opsonophagocytosis or by
neutralizing Hyr1 killing resistance, we isolated and prepared
F(ab9) 2 fragments from pooled IgG raised against the 8 peptides of
Hyr1p (conjugated to keyhole limpet hemocyanin or KLH) or from
non-specific, rabbit control IgG. These fragments were used in HL-
60 derived neutrophil killing assay against C. albicans conditionally
overexpressing or suppressing Hyr1p rather than wild-type C.
albicans to demonstrate specificity of these fragments to Hyr1p and
not to other members of IFF family [9]. Consistent with our
previous mouse IgG data [12], we found that F(ab9) 2 fragments
prepared from anti-Hyr1p antibodies but not those prepared from
control antibodies were able to restore HL-60 derived neutrophil
killing of the HYR1 conditional expressing strain to levels equivalent
to that of the suppressing strain (Figure 4D).
To verify that the protection elicited by antibodies was indeed due
to anti-Hyr1p antibodies and not due to non-specific protection
caused by antibodies reacting to unrelated immunogen such as
peptide carrier protein KLH, the purified IgG targeting the 8
hydrophilic rHyr1p-N peptides was absorbed with C. albicans hyphae
prior to testing for their protective activity against hematogenously
disseminated candidiasis. The absorbed IgG did not stain C. albicans
hyphae (Figure 5A), indicating the anti-Hyr1p IgG were successfully
eliminated. Furthermore, similar to non-specific, rabbit control IgG,
the absorbed IgG did not protect mice from C. albicans infection,
whereas the purified, non-absorbed IgG did (Figure 5B, P= 0.002).
The rHyr1p-N vaccine substantially reduced tissue fungal
burden in BALB/c mice challenged with several non-
albicans species of Candida
A vaccine that elicits protection against C. albicans and other
non-albicans species is highly desirable because a significant
Figure 1. rHyr1p-N vaccine improved survival and decreased
fungal burden in mice with C. albicans infection. (A) Survival of
vaccinated or control mice (n = 15 per group) infected intravenously
with C. albicans 15563 strain, a clinical isolate (96105 per dose),
* P,0.001 compared to alum alone by the log-rank test. (B) Kidney
fungal burden of mice (n = 10 per arm) vaccinated with 33 mg rHyr1p-N
+ alum or alum alone and harvested 3 days post infection with C.
albicans 15663 (76105 per dose). Data are presented as median 6
interquartile ranges. * P,0.001 compared to results obtained from
kidneys harvested from mice vaccinated with alum alone by the Mann-
Whitney U test.
doi:10.1371/journal.pone.0025909.g001
rHyr1p as Candida Vaccine
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number of Candida infections are caused by non-albicans species.
For example, C. glabrata represents the second most common cause
of candidiasis and C. krusei is resistant to azole therapy. Using blast
searches we were able to detect Hyr1p like molecules in several
Candida species with amino acid similarity ranging between 47–
72% in certain areas. Thus, we vaccinated mice with rHyr1p-N
Figure 2. Representative histopathological sections from kidneys were shown. (A) Control mice infected with C. albicans had multiple
abscesses showing mostly yeast forms with some hyphae and pseudohyphae throughout the kidneys. (B) rHyr1p-N vaccinated mice (33 mg) infected
with C. albicans had less abscesses with far less fungi visible. (C) Semiquantitative evaluation of the severity of infection indicated significant abscess
and Candida cells reduction in vaccinated mice compared to control mice. Sections were stained by PAS. Thirty random fields were examined by a
blinded assessor (GL) to assess the number of lesions per field. Number of organisms per lesion was evaluated in 120 lesions in the control
unvaccinated mice. The average number of organisms per lesion was determined by dividing the total number of fungal cells by the number of
lesions counted. * P,0.0001 by Wilcoxon rank sum test.
doi:10.1371/journal.pone.0025909.g002
Figure 3. rHyr1p-N vaccine prolonged survival and decreased fungal burden in neutropenic mice infected with C. albicans. Balb/c
mice (n = 20 per arm) were vaccinated with rHyr1p-N mixed with alum or alum alone (control), treated with cyclophosphamide, and then infected
with C. albicans 15563 at 16105 blastospores. Two days before cyclophosphamide treatment, half of the mice were bled and individually marked for
antibody titer using ELISA (A) (rHyr1p-N vaccinated versus control, *P=1.08E-05 by Wilcoxon rank-sum test) and survival (B) (rHyr1p-N vaccinated
versus control, *P=0.007 by log rank test). The other half mice were used for fungal burden (C) * P= 0.002 by Wilcoxon rank-sum test.
doi:10.1371/journal.pone.0025909.g003
rHyr1p as Candida Vaccine
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plus alum as above, then challenged with C. albicans, C. glabrata, C.
krusei, C. parapsilosis, or C. tropicalis. Three days post infection mice
were sacrificed and the kidneys harvested for determination of
tissue fungal burden through colony counts. Mice vaccinated with
rHyr1p-N had 0.65–1.69 log decrease in kidney fungal burden
compared to mice vaccinated with alum alone (Figure 6,
P,0.001).
Discussion
C. albicans vaccine development has focused on using cell surface
components [18,19], peptides derived from cell wall proteins as
immunogens [20], or on antibodies targeting cell surface
components [21,22]. Our group has been working for decades
towards developing immunotherapeutic approaches to prevent or
ameliorate disseminated, healthcare-associated fungal infections.
These efforts have resulted in the initiation of a Phase I clinical
trial of our anti-Candida vaccine that targets the Als3p, a known
adhesin/invasion [23].
In our efforts to develop additional protective antigens against
Candida, we have identified properties of the recombinant N-
terminus of Hyr1p (rHyr1p-N) [12] that make it highly desirable
for further development as both active and passive immunother-
apy target. In our previous study, we demonstrated by using
indirect immunofluorescence that Hyr1p is expressed on the cell
surface of C. albicans hyphae [12]. These findings were further
confirmed by our comparative indirect immunofluorescence of C.
albicans using purified IgG raised against 8 hydrophilic peptides of
rHyr1p-N pre- and post-absorption with C. albicans hyphae and
Table 1. Hyr1 peptides used in this study.
Peptide
Number Sequence
MW
(kDa) pI
Purity
(%) Source
1 CGPSAPESESDLNTP 1.5 3.44 86.1 This study
2 CGNRDHFRFEYYPDT 1.9 5.69 99.4 This study
3 CGYDSKLFRIVNSRG 1.7 9.16 95.7 This study
4 CKIKGTGCVTADEDT 1.5 4.70 86.4 This study
5 CLKNAVTYDGPVPNN 1.6 6.25 94.1 This study
6 NSKSSTSFSNFDIGC 1.6 6.25 91.4 This study
7 CEPTHNFYLKDSKSS 1.8 7.19 85.8 This study
8 TSRIDRGGIQGFHGC 1.6 8.27 91.8 This study
Additional cysteine residues on the N- or C-termini were used to conjugate the
14-mer peptide to KLH.
doi:10.1371/journal.pone.0025909.t001
Figure 4. Dose dependent passive immunization with anti-Hyr1p IgG protected against murine hematogenously disseminated
candidiasis. Mice were given 0.3 mg (A), 1 mg (B) and 3 mg (C) of anti-Hyr1p IgG by intraperitoneal injection 2 hr before infecting with 6.26105
blastospores of Candida albicans 15563 via the tail vein. Survival of mice (n = 10 per group) was monitored twice daily. * P= .001 by log-rank test vs.
mice receiving non-specific, rabbit control IgG. (D) Effect of vaccinated or control F(ab9) 2 on blocking HL-60 derived neutrophil killing of C. albicans. C.
albicans overexpressing or suppressing Hyr1p were used in the assay to demonstrate specificity of the F(ab9) 2 fragments to Hyr1p. Control denotes
assay performed either in the absence of F(ab9) 2 or in the presence of F(ab9)2 from non-specific, rabbit control IgG. Data are displayed as median 6
interquartile range. * P= .001 by Mann-Whitney test.
doi:10.1371/journal.pone.0025909.g004
rHyr1p as Candida Vaccine
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control IgG (Figure 5A). We hypothesized that immunotherapies
targeting the cell wall Hyr1p would have the dual benefit of the
immune system recognizing the fungus and enhancing phagocyte
killing of Candida. In this study, our data on rHyr1p-N has shown
efficacy in animal models at doses 10–30 times less than those used
for rAls3p-N (i.e. ,50% survival for 10–33 mg dose for rHyr1p- N
vs. 300 mg dose of rAls3p-N) [12,19,24]. Additionally, the
mechanism of action appears to be considerably different from
that of rAls3p-N. Rabbit polyclonal IgG raised against 8 different
14-mer peptides from regions of rHyr1p-N substantially protects
mice from experimental disseminated candidiasis, whereas, our
previous studies indicated that the mechanism of action of the
rAls3p-N vaccine is dominantly dependent on T cells and anti-
rAls3p-N antibodies are not the central mechanism of protection
[19,24]. Furthermore, the rHyr1p-N maintained its efficacy in the
neutropenic mouse model. These findings suggest that Hyr1p is a
promising target for both active and passive immunization.
Tissue fungal burden and histopathological examination of
kidneys harvested from mice vaccinated with rHyr1p-N or alum
alone further confirmed the efficacy of the rHyr1p-N vaccine.
However, it appears that the histopathology difference between
the control (Figure 2A) and rHyr1p-N vaccinated mice (Figure 2B)
was more prominent than that of tissue fungal burden of the same
organs. In this regard, it has been previously reported that colony
counting can underestimate the tissue fungal burden in the
presence of hyphae and pseudohyphae [25,26], likely because
tissue homogenization kills fungal filaments. We found that control
mice had significantly more filamentous fungi in kidneys than
vaccinated mice which had less abscesses mainly consisting of yeast
form fungal elements. Therefore, tissue homogenization likely
artificially lowers the colony counts for kidneys harvested from
control mice but not from rHyr1p-N-vaccinated mice, making the
difference less prominent.
Our results also show a dose response of anti-Hyr1p IgG in
protecting mice from disseminated candidiasis. We confirmed that
the protection elicited by anti-Hyr1p IgG was specific to Hyr1p
since absorbed IgG with C. albicans hyphae lost its ability to protect
mice against hematogenously disseminated candidiasis (Figure 5B).
These results suggest that the mechanism of protection rendered
by rHyr1p-N appears to be attributed, at least in part, to protective
antibody response. Further studies to elucidate the role of T-cells
vs. B-cells in the mechanism of rHyr1p-N protection against
disseminated candidiasis are currently under active investigation.
In this study, we show that pooled IgG raised against 8 Hyr1
peptides directly neutralized the function of Hyr1p in resisting
phagocyte killing rather than enhanced opsonophagocytosis. This
Figure 5. Protection against hematogenously disseminated candidiasis using purified pooled IgG was specific to Hyr1p. A) Indirect
immunofluorescence with rabbit anti-Hyr1p IgG demonstrated surface expression of Hyr1p on C. albicans hyphae and the successful absorption of
anti-Hyr1p antibodies; B) Survival of mice treated with 1 mg of: 1) pooled anti-Hyr1p IgG (n = 20); 2) pooled anti-Hyr1p IgG absorbed with C. albicans
hyphae (n = 10); or 3) rabbit control IgG (n = 20) 2 hr before infecting with 8.76105 blastospores of C. albicans 15563 via the tail vein. The antibody
dose was repeated 3 days after infection. * P= 0.002 for pooled anti-Hyr1p IgG vs. absorbed IgG, * P= 0.03 for pooled anti-Hyr1p IgG vs. control IgG,
** P= 0.28 for control IgG vs. absorbed IgG by Log Rank test.
doi:10.1371/journal.pone.0025909.g005
rHyr1p as Candida Vaccine
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is evident by the ability of F(ab9)2 fragments (prepared from anti-
rHyr1p-N antibodies) to restore phagocyte killing of C. albicans
overexpressing Hyr1p to levels equivalent to that of the
suppressing strain (Figure 4D). However, the rHyr1p-N vaccine
maintained its efficacy in neutropenic mice. This can be explained
by the fact that cyclophosphamide induces leukopenia in mice
with minimal effect on tissue phagocytes. Further experimentation
is necessary to determine specific peptide(s) by which antibodies
are generated to protect the host against disseminated candidiasis.
In summary, the rHyr1p-N vaccine is a promising candidate for
further development. The vaccine is efficacious in both immuno-
competent and immunocompromised mice, when mixed with
alum as an adjuvant, against multiple clinical isolated strains of C.
albicans [12], and against several non-albicans Candida species.
Materials and Methods
Candida strains and growth conditions
C. albicans 15663, C. glabrata 31028, C. parapsilosis 22019 and C.
tropicalis 4243 are clinical bloodstream isolates collected from
Harbor-UCLA Medical Center. C. krusei 91-1159 was generously
provided by Michael Rinaldi, San Antonio, TX). C. albicans strains
CAAH-31 and THE31 were engineered as described in our
previous study and doxycycline was used to regulate the HYR1
expression [12]. All tested strains were routinely grown in YPD
(2% Bacto Peptone, 1% yeast extract, 2% dextrose). Cell densities
were determined by counting in a hemacytometer.
rHyr1p-N production
66His tagged rHyr1p-N was produced in E. coli and purified by
Ni-agarose affinity column as previously described [12]. Endotoxin
was removed from rHyr1p-N using ProteoSpin Endotoxin
Removal kit (Norgen Bioteck Corporation, Ontario, Canada),
and the endotoxin level was determined with Limulus Amebocyte
Lysate endochrome (Charles River Laboratories, Wilmington,
MA) per manufacturer’s instruction. Using this procedure,
endotoxin was reduced to ,0.1 EU per dose of the vaccine.
Synthetic peptides and rabbit anti-Hyr1p polyclonal
antibodies
Eight peptides derived from rHyr1p-N (Table 1) were
commercially synthesized and used to generate anti-Hyr1p antibo-
dies. Peptides were .85% pure as determined by HPLC and mass
spectrometry (GenScript, Piscataway, NJ). They were conjugated
to keyhole limpet hemocyanin (KLH) through additional cysteine
from either N- or C- terminus before raising rabbit antiserum
individually using a standard immunization protocol (GenScript,
Piscataway, NJ). Total IgG from pooled serum was affinity purified
using Pierce Protein A plus Agarose (Thermo Scientific, Rockford,
IL) per the manufacturer’s instruction prior to administering in
passive immunization studies.
Immunofluorescence detection of Hyr1p cellular
localization
Indirect immunofluorescence was performed using pooled
rabbit anti-Hyr1p IgG raised against 8 peptides of rHyr1p-N as
previously described [12]. In brief, C. albicans blastospores (16107)
were pre-germinated in RPMI 1640 for 90 min at 37uC and
transferred into a 4-well chamber slide (Nalge Nunc International).
After incubation at 4uC for 30 min, the cells were blocked with
300 ml of 1.5% mouse serum, then stained with 1:500 dilution of
either 1) pooled anti-Hyr1p IgG, 2) pooled anti-Hyr1p IgG
absorbed with C. albicans hyphae (by incubating the pooled IgG
repeatedly for 4 times with 16107 C. albicans hyphae for 30 min
each time on ice), or 3) rabbit control IgG. The cells were
counterstained with fluorescein isothiocyanate (FITC)-labeled goat
anti-rabbit IgG at 1:100 dilution prior to imaging with Zeiss
Axioskop fluorescence microscopy.
Immunization protocol and animal studies
All active vaccinations were conduced as previously described
[12]. In brief, juvenile (10–12 week) Balb/C mice were vaccinated
subcutaneously with 30 mg of rHyr1p-N mixed with alum (2%
Alhydrogel; Brenntag Biosector, Frederikssund, Denmark) as an
adjuvant in phosphate buffered saline (PBS) on day 0, boosted with
the same dose on day 21, then infected via the tail vein on day 35
[27]. Control mice were vaccinated with alum alone.
To test the efficacy of the vaccine in immunocompromised
mice, mice were vaccinated as above prior to inducing
neutropenia by intraperitoneal injection of 200 mg/kg of
cyclophosphamide on day 22 followed by another dose of
100 mg/kg on day +7 relative to infection. This regimen results
in approximately 10 days of leucopenia with reduction in
neutrophil, lymphocyte and monocyte counts, as described
previously [28,29,30]. For both immunocompetent and neutro-
penic mice differences in survival between vaccinated and
adjuvant vaccinated mice were compared by the Log Rank test.
For passive immunization, immune IgG was administered
intraperitoneally to naı¨ve mice 2 hr before infecting intravenously
with C. albicans. Control mice were given non-specific, rabbit IgG
(Innovative Research, USA). IgG doses were repeated 3 days after
infection, and survival of mice was monitored twice daily.
Quantitative culturing of kidneys from vaccinated or control
mice infected with different species of Candida was performed as
previously described [31]. In brief, mice were infected through tail
veins. Kidneys were harvested 3 days post infection, homogenized,
serially diluted in 0.85% saline, and quantitatively cultured on
YPD that contained 50 mg/ml chloramphenicol. Colonies were
Figure 6. rHyr1p-N vaccine reduces tissue fungal burden in
BALB/c mice infected with non-albicans species of Candida.
BALB/c mice (n = 10 per group) were vaccinated with alum or alum plus
rHyr1p-N (30 mg) and boosted three weeks later. Two weeks after the
boost, mice were challenged via the tail vein with C. glabrata (3.26107),
C. krusei (3.46107), C. parapsilosis (9.66106), or C. tropicalis (3.26106).
Kidney fungal burden was determined on day 3 post infection. The y
axis reflects the lower limit of detection of the assay. * P,0.001 versus
adjuvant control by the Mann-Whitney U test.
doi:10.1371/journal.pone.0025909.g006
rHyr1p as Candida Vaccine
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counted after incubation of the plates at 37uC for 24 to 48 hr, and
results were expressed as log CFU per gram of infected organ.
Concomitant with the fungal burden experiment, kidneys were
removed aseptically from two mice per group for histopathological
examination. Kidneys were immersed in zinc formalin fixative
until examination. Fixed organs were dehydrated in graded
alcohol solutions, embedded in paraffin, and cut into 6-mm-thick
sections. Mounted sections were stained with Gomori methena-
mine silver and examined by light microscopy [32].
Enzyme-linked immunosorbent assay (ELISA)
To test if the rHyr1p-N vaccine induced an immune response,
antibody titers of serum samples collected from vaccinated and
control mice were determined by ELISA in 96-well plates as
previously described [27]. Wells were coated at 100 ml per well
with rHyr1p-N at 5 mg/ml in PBS. Mouse sera were incubated for
1 hr at room temperature following a blocking step with Tris-
buffered saline (TBS; 0.01 M Tris HCl [pH 7.4], 0.15 M NaCl)
containing 3% bovine serum albumin. The wells were washed
three times with TBS containing 0.05% Tween 20, followed by
another three washes with TBS. Goat anti-mouse secondary
antibody conjugated with horseradish peroxidase (Sigma) was
added at a final dilution of 1:5000, and the plate was further
incubated for 1 hr at room temperature. Wells were washed with
TBS and incubated with substrate containing 0.1 M citrate buffer
(pH 5.0), 50 mg of o-phenylenediamine (Sigma), and 10 ml of 30%
H2O2. The color was allowed to develop for 30 min, after which
the reaction was terminated by addition of 10% H2SO4 and the
optical density (OD) at 490 nm was determined in a microtiter
plate reader. Negative control wells received only diluent, and
background absorbance was subtracted from the test wells to
obtain final OD readings. The ELISA titer was taken as the
reciprocal of the last serum dilution that gave a positive OD
reading (i.e., more than the mean OD of negative control samples
plus 2 standard deviations).
F(ab9) 2 blocking assay
To study the mechanism of protection mediated by anti-Hyr1p
antibodies in phagocyte-mediated killing of C. albicans, HL-60 cells
that have been differentiated to neutrophil-like phenotype were
used [12]. Killing assay was conducted in the presence of anti-
Hyr1p IgG or F(ab9) 2 fragments as described before [12]. In brief,
HL-60 cells were induced with 2.5 mM of retinoic acid and 1.3%
DMSO for 3 days at 37uC with 5% CO2. Immune anti-Hyr1
peptides (Table 1) sera were pooled and total IgG was isolated
using protein A agarose (Thermo Scientific). Serum collected from
the same rabbits prior to immunization with the peptides served as
control serum. The F(ab9) 2 fragments from immune or control
IgG were purified with Pierce F(ab9)2 Preparation Kit according to
the manufacturer’s instruction. SDS-PAGE analysis indicated
.95% of Fc fragment was digested by this kit (data not shown).
Next, C. albicans cells overexpressing or suppressing Hyr1p [12]
were incubated with 50 mg/ml of vaccinated or control F(ab9) 2
fragments on ice for 45 min. C. albicans cocultured with the F(ab9) 2
fragments were incubated with HL-60 derived neutrophils for 1 hr
at 37uC with 5% CO2 prior to sonication and quantitative
culturing on YPD plates. % killing was calculated by dividing the
number of CFU after coculturing with HL-60 derived neutrophils
by the number of CFU from C. albicans incubated with media
without HL-60 derived neutrophils.
Statistical analysis
The nonparametric log rank test was used to determine
differences in the survival times of the mice. Neutrophil killing
assay, titers of antibody, and tissue fungal burden were compared
by the Mann-Whitney U test or Wilcoxon rank sum test for
unpaired comparisons. Correlations were calculated with the
Spearman rank sum test. P values of ,0.05 were considered
significant.
All procedures involving mice were approved by the Los
Angeles Biomedical Research Institute animal use and care
committee for the project 11672-05 specifically to this vaccine
study, following the National Institutes of Health guidelines for
animal housing and care. The institute has a US Public Health
Service approved animal welfare assurance number A3330-01.
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